Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

• Status: Not yet recruiting
• Trial end date: 2024-05-09
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of tozorakimab as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen on the prevention of death or progression to IMV/ECMO.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Adult participants ≥ 18 years old at the time of signing the informed consent form.

• Patients hospitalised with viral lung infection.

• Hypoxaemia requiring treatment with supplemental O2

Exclusion Criteria:

• Known fungal or parasitic lung infection, aspiration lung infection, lung abscess, or pulmonary sepsis. Bacterial co-infection is allowed, unless, in the opinion of the investigator, bacterial infection defines the severity of the participant's condition.

• Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology.

• Ongoing or impending IMV/ECMO at randomisation.